Current Report Filing (8-k)
June 06 2017 - 4:26PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
_______________________________
FORM
8-K
_______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 6, 2017
_______________________________
PEREGRINE
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-32839
|
|
95-3698422
|
(State of other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
14282 Franklin Avenue, Tustin, California 92780
|
(Address of Principal Executive Offices)
|
|
|
|
|
|
Registrant’s telephone number, including area code:
(714) 508-6000
|
|
Not Applicable
|
(Former name or former address, if changed since last report)
_______________________________
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o
Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
On June 6, 2017, Peregrine
Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the declaration by the Company’s Board
of Directors of a quarterly cash dividend payment of $0.65625 per share (the “Dividend”) on the Company’s 10.50%
Series E Convertible Preferred Stock (the “Series E Preferred Stock”), accruing from April 1, 2017 through June 30,
2017. The Dividend equates to an annualized 10.50% per share of Series E Preferred Stock based on the $25.00 per share stated liquidation
preference. The Dividend on the Series E Preferred Stock is payable on July 3, 2017 to holders of record at the close of business
on June 19, 2017. A copy of the press release is filed hereto as Exhibit 99.1.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits. The following material is
filed as an exhibit to this Current Report on Form 8-K:
Exhibit
Number
99.1 Press
Release issued June 6, 2017.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: June 6, 2017
|
PEREGRINE PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Paul J. Lytle
|
|
|
Paul J. Lytle
Chief Financial Officer
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
|
|
|
99.1
|
Press Release issued June 6, 2017.
|
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Sep 2023 to Sep 2024